News from the FDA/CDC
News from the FDA/CDC
Developmental disabilities up significantly since 2014
Autism spectrum disorder was almost three times as prevalent in boys as in girls in 2014-2016.
FDA/CDC
New buprenorphine formulation approved for medication-assisted treatment
Patients who are currently taking other buprenorphine formulations can be transitioned.
FDA/CDC
FDA clears first-ever neurostimulation device for opioid withdrawal symptoms
In one study, almost 90% of patients transitioned to medication-assisted treatment after 5 days of using the device.
Latest News
Adherence boon, or Big Brother loom?
Take our poll on the first drug approved in the United States with a digital ingestion tracking system.
FDA/CDC
FDA approves cariprazine for schizophrenia maintenance treatment
Approval is based on results of a 72-week double-blind, randomized study of three daily doses of the antipsychotic, compared with placebo.
From the Journals
Public health hazard: Bring your flu to work day
Many physicians and pharmacists report working while having influenza-like illness.
FDA/CDC
FDA panels support two NDAs for buprenorphine subcutaneous injections
The panelists agree that subcutaneous formulations might help step the opioid epidemic.
News from the FDA/CDC
Fentanyl analogues an increasing factor in opioid deaths
Almost 30% of opioid overdose deaths in Maine involved carfentanil or similar products.
Latest News
Suicide rate highest in rural areas
Gap between rural and large U.S. metropolitan counties widened between 2001 and 2015.
News from the FDA/CDC
Payment gaps seen for child visits
Private insurance costs are consistently higher than Medicaid since 2010, with geographic and specialty variation.
FDA/CDC
Do not withhold opioid addiction drugs from patients taking benzodiazepines
The FDA says the benefits of combining MAT drugs with CNS depressants outweigh the risks.